| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003395530 |
| P356 | DOI | 10.1186/1475-2875-13-141 |
| P932 | PMC publication ID | 3989846 |
| P698 | PubMed publication ID | 24731238 |
| P5875 | ResearchGate publication ID | 261732761 |
| P50 | author | Mark Hickman | Q43186320 |
| P2093 | author name string | Jing Zhang | |
| Qiang Zeng | |||
| Lisa Xie | |||
| Qigui Li | |||
| Victor Melendez | |||
| Brandon Pybus | |||
| Diana Caridha | |||
| Michael O'Neil | |||
| P2860 | cites work | Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging | Q27335248 |
| Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery | Q27861956 | ||
| A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria | Q28204425 | ||
| 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models | Q28335570 | ||
| In vivo imaging of malaria parasites in the murine liver | Q33291322 | ||
| Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects | Q33613720 | ||
| Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. | Q33696465 | ||
| Quantitative bioluminescent imaging of pre-erythrocytic malaria parasite infection using luciferase-expressing Plasmodium yoelii | Q34674176 | ||
| Evaluation of immunity against malaria using luciferase-expressing Plasmodium berghei parasites | Q35761522 | ||
| 4(1H)-Quinolones with liver stage activity against Plasmodium berghei. | Q36505423 | ||
| Tafenoquine: a promising new antimalarial agent | Q36802630 | ||
| Quantitative analysis of Plasmodium berghei liver stages by bioluminescence imaging | Q39276004 | ||
| In vitro activity of tafenoquine alone and in combination with artemisinin against Plasmodium falciparum | Q39381337 | ||
| Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives | Q39622533 | ||
| Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse | Q41913336 | ||
| Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand | Q41923249 | ||
| Reduced Plasmodium berghei sporozoite liver load associates with low protective efficacy after intradermal immunization | Q41927711 | ||
| The efficacy of WR238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivax | Q41934435 | ||
| The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. | Q41936641 | ||
| Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR Mice and Anopheles stephensi mosquitoes | Q44142648 | ||
| Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. | Q44158438 | ||
| Simple Centrifugation Method for Rapid Separation of Sporozoites from Mosquitoes | Q44164986 | ||
| Plasmodium liver load following parenteral sporozoite administration in rodents | Q44166267 | ||
| A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum | Q44320940 | ||
| Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel | Q44354530 | ||
| Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria | Q45056153 | ||
| Development and validation of flow cytometric measurement for parasitemia in cultures of P. falciparum vitally stained with YOYO-1. | Q47823279 | ||
| Development and validation of flow cytometric measurement for parasitaemia using autofluorescence and YOYO-1 in rodent malaria. | Q47830770 | ||
| First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. | Q47831031 | ||
| Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites | Q47915637 | ||
| Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats | Q68054030 | ||
| In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei | Q68468347 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 141 | |
| P577 | publication date | 2014-04-14 | |
| P1433 | published in | Malaria Journal | Q15749954 |
| P1476 | title | Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections | |
| P478 | volume | 13 |
| Q47627038 | A newly validated high-performance liquid chromatography method with diode array ultraviolet detection for analysis of the antimalarial drug primaquine in the blood plasma |
| Q47764632 | Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria. |
| Q62125563 | Approval of Tafenoquine for Malaria Chemoprophylaxis |
| Q40388332 | Artesunate-tafenoquine combination therapy promotes clearance and abrogates transmission of the avian malaria parasite Plasmodium gallinaceum. |
| Q37480757 | Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei |
| Q35746028 | Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics |
| Q92249482 | Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials |
| Q34646141 | Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review |
| Q28085135 | Enlightening the malaria parasite life cycle: bioluminescent Plasmodium in fundamental and applied research |
| Q30976084 | Hemoglobin E and Glucose-6-Phosphate Dehydrogenase Deficiency and Plasmodium falciparum Malaria in the Chittagong Hill Districts of Bangladesh |
| Q50054503 | Identification of a Novel CD8 T Cell Epitope Derived from Plasmodium berghei Protective Liver-Stage Antigen |
| Q35692516 | Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy |
| Q37712176 | Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum |
| Q28081463 | Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax |
| Q33607991 | Long-Term Prophylaxis and Pharmacokinetic Evaluation of Intramuscular Nano- and Microparticle Decoquinate in Mice Infected with P. berghei Sporozoites. |
| Q57465375 | Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics |
| Q36907360 | Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants |
| Q64996994 | Primaquine-quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species. |
| Q37287860 | Single-Dose Primaquine in a Preclinical Model of Glucose-6-Phosphate Dehydrogenase Deficiency: Implications for Use in Malaria Transmission-Blocking Programs. |
| Q26741307 | Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date |
| Q92315822 | Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria |
| Q38774112 | The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg). |
| Q64245769 | Updating the modified Thompson test by using whole-body bioluminescence imaging to replace traditional efficacy testing in experimental models of murine malaria |
Search more.